A critical assessment of brazil’s emerging pharmaceutical market

Resumo

Brazil has emerged as a leader in new sites selected for clinical trials, by offering a multitude of benefits to sponsors. Even though there are significant delays with regulatory timelines, it provides highly qualified investigators, low costs, a strong infrastructure, well-established ethical support, and high patient recruitment and adherence rates. However, in order to become a primary location for clinical trials, Brazil will have to streamline and improve regulatory processes and the current political and financial conditions. The study was conducted with consensus judgement and analysis of 15 experienced industry reviewers have provided informative descriptive data. The findings suggest areas in new clinical trial in which strategies for workflow and process development could improve efficiency of clinical development.

Ficha do documento

Tipo

Dissertação

Ano

2016

Instituição

Fundação Getulio Vargas

Fonte

Repositório da FGV

Idioma

Inglês

Acesso

Não informado

Identificador

oai:repositorio.fgv.br:10438/17977

Temas

Desenvolvimento Econômico

Palavras-chave

CriticalAssessmentBrazilEmergingPharmaceuticalMarketAdministração de empresasPlanejamento empresarial - BrasilIndústria farmacêutica - Brasil